Blog
Mitchells & Butlers H1 Earnings Call Highlights
Mitchells & Butlers (LON:MAB) said first-half trading remained ahead of the wider market, with management pointing to resilient sales, cost controls and balance sheet progress despite weaker
Smiths Group Q3 Earnings Call Highlights
Key Points
- Interested in Smiths Group plc? Here are five stocks we like better.
- Smiths Group cut its full-year organic revenue growth outlook to about 2% from 3% to 4% after Middle
AJ Bell H1 Earnings Call Highlights
Key Points
- Interested in AJ Bell plc? Here are five stocks we like better.
- AJ Bell delivered strong first-half growth, with platform customers up 79,000 to 723,000 and record net inflows of
easyJet H1 Earnings Call Highlights
Key Points
- Interested in easyJet plc? Here are five stocks we like better.
- easyJet reported a wider first-half loss of GBP 552 million, with results pressured by higher fuel costs, legal
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins
Key Points
- Interested in Compass Pathways PLC Sponsored ADR? Here are five stocks we like better.
- Compass Pathways said it remains on track to file a New Drug Application for COMP360 in Q4
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
Key Points
- Interested in Climb Bio, Inc.? Here are five stocks we like better.
- Budoprutug, Climb Bio’s CD19-targeting antibody, is the company’s lead asset, with early data showing complete
Charter Communications Eyes Cash Flow Lift as Network Upgrades, Cox Deal Advance
Charter Communications (NASDAQ:CHTR) Chief Financial Officer Jessica Fischer said the company’s top priority remains growing its connectivity
Check Point Software Technologies Eyes Firewall Rebound After Sales Overhaul
Key Points
- Interested in Check Point Software Technologies Ltd.? Here are five stocks we like better.
- Check Point says it has largely moved past the most disruptive phase of its go-to-market
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
Key Points
- Interested in CG Oncology, Inc.? Here are five stocks we like better.
- Cohort CX data for cretostimogene plus gemcitabine showed a positive safety and efficacy signal in bladder
CDW Touts AI Factory Demand, Recurring Revenue Push at JPMorgan Conference
Key Points
- Interested in CDW Corporation? Here are five stocks we like better.
- AI demand is moving from experimentation to production, with CDW saying customers now want help deploying AI
AEVEX Q1 Earnings Call Highlights
Key Points
- Interested in AEVEX Corp.? Here are five stocks we like better.
- Revenue and profit surged in AEVEX’s first quarter, with revenue up 307% year over year to $216.7 million and net
Urban Outfitters Q1 Earnings Call Highlights
Key Points
- Interested in Urban Outfitters, Inc.? Here are five stocks we like better.
- Urban Outfitters posted another record quarter, with first-quarter fiscal 2027 sales up 11% to $1.5
StepStone Group Q4 Earnings Call Highlights
Key Points
- Interested in StepStone Group Inc.? Here are five stocks we like better.
- StepStone posted record fee-related earnings in fiscal Q4 2026, with FRE of $105 million, up 12% year over
NVIDIA Q1 Earnings Call Highlights
Key Points
- Interested in NVIDIA Corporation? Here are five stocks we like better.
- NVIDIA posted record Q1 fiscal 2027 results, with revenue of $82 billion, up 85% year over year, while
e.l.f. Beauty Q4 Earnings Call Highlights
Key Points
- Interested in e.l.f. Beauty? Here are five stocks we like better.
- e.l.f. Beauty posted strong fiscal 2026 results, with net sales up 25% and adjusted EBITDA up 13%, extending its
CCC Intelligent Solutions Enters Next AI Phase as Products Scale With Major Customers
Key Points
- Interested in CCC Intelligent Solutions Holdings Inc. Common Stock? Here are five stocks we like better.
- CCC Intelligent Solutions says its AI products are moving from testing into
Biosig Technologies Q1 Earnings Call Highlights
Key Points
- Interested in Biosig Technologies, Inc.? Here are five stocks we like better.
- Streamex said Q1 2026 was a shift from preparation to commercialization, highlighted by the launch of
Belite Bio Q1 Earnings Call Highlights
Key Points
- Interested in Belite Bio, Inc. Sponsored ADR? Here are five stocks we like better.
- Belite Bio said it has started a rolling NDA submission to the FDA for Tinlarebant in Stargardt
Intuit Q3 Earnings Call Highlights
Key Points
- Interested in Intuit Inc.? Here are five stocks we like better.
- Intuit beat third-quarter expectations, with revenue up 10% to $8.6 billion and earnings above guidance. The company
Booking CEO Sees AI, Connected Trips Driving Long-Term Travel Growth
Key Points
- Interested in Booking Holdings Inc.? Here are five stocks we like better.
- CEO Glenn Fogel said Booking Holdings is focused on long-term growth despite near-term travel uncertainty
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook
Key Points
- Interested in Eli Lilly and Company? Here are five stocks we like better.
- Eli Lilly saw a huge gain after its recent earnings report, but the wins didn't stop there
- Lilly also recently
AI Consolidation Begins: Blackstone & Google Forge an AI Empire
Key Points
- Interested in Alphabet Inc.? Here are five stocks we like better.
- The partnership between Blackstone and Google signals a major consolidation in the AI sector backed by a significant
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
Key Points
- Interested in Beam Therapeutics Inc.? Here are five stocks we like better.
- Beam Therapeutics said its sickle cell disease candidate, risto-cel, could be ready for a BLA filing as
CorVel Q4 Earnings Call Highlights
Key Points
- Interested in CorVel Corp.? Here are five stocks we like better.
- CorVel posted solid fiscal 2026 growth, with revenue up 7% to $959 million and EPS up 17% to $2.14. In the March
TJX Companies Q1 Earnings Call Highlights
Key Points
- Interested in The TJX Companies, Inc.? Here are five stocks we like better.
- TJX beat expectations in Q1 with consolidated comparable sales up 6% and diluted EPS of $1.19, as